Sepsis – Epidemiology – Mature Markets
Clarivate Epidemiology’s coverage of sepsis comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the incidence of sepsis for each country, as well as annualized case counts projected to the national population.
Clarivate Epidemiology’s sepsis forecast will answer the following questions:
- How will demographic trends such as population aging and improving life expectancy affect the epidemiology of sepsis over the forecast period?
- Of all people diagnosed with sepsis, how many in each of the mature pharmaceutical markets are drug-treated?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as a part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology provides at least 10 years of forecast data for the following sepsis patient populations:
- Diagnosed events.
- Diagnosed events by severity.
- Severe sepsis by primary site of infection.
- Severe sepsis by pathogen.
Note: Coverage may vary by country and region.
Table of contents
- Sepsis - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Event Rate of Sepsis per 1,000 People of All Ages in 2021 and 2031
- Event Rate of Sepsis per 1,000 People of All Ages in 2021 and 2031
- Relative Sizes of Contributing Factors to the Trend in the Events of Sepsis Over the Next 10 Years
- Relative Sizes of Contributing Factors to the Trend in the Prevalent Cases of Sepsis Over the Next 10 Years
- Analysis of Diagnosed Events of Sepsis by Pathogen
- Analysis of Diagnosed Events of Sepsis by Pathogen
- Epidemiology Data
- Methods
- Reference Materials
- Introduction
Yueyao (Alex) Li, M.D., Ph.D., M.S.P.H., is an associate epidemiologist at Clarivate. Previously, she was a postdoctoral researcher at Brown University, where she worked on projects relating to skin cancer and chronic skin conditions. Dr. Li holds a medical degree specializing in general surgery from China Medical University. She also holds a Ph.D. in epidemiology from Indiana University and a master’s degree in public health from the University of South Carolina.
Oliver Blandy, M.Sc., is a senior epidemiologist at Clarivate. Previously, Oliver worked as a research assistant for Imperial College London, where he was the lead for several studies within an NIRH-funded research group investigating healthcare-associated infections and antimicrobial resistance. He holds an M.Sc. from the University of Bristol, where he specialized in nutrition, physical activity, and public health. He also holds a B.Sc. in chemistry and a postgraduate certificate in education, both from the University of Bristol.